Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
Holding CCCC?
Track your performance easily
CCCC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.06 - $11.88
Previous Close$4.05
Volume287.44K
Average Volume (3M)1.00M
Market Cap
$295.84M
Enterprise Value$104.40M
Total Cash (Recent Filing)$255.64M
Total Debt (Recent Filing)$67.09M
Price to Earnings (P/E)―
Beta3.70
Next Earnings
Feb 20, 2025EPS Estimate
-$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding70,588,959
10 Day Avg. Volume1,055,762
30 Day Avg. Volume1,003,640
Standard Deviation0.44
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.18
Price to Sales (P/S)8.70
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit5.03
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$10.67Price Target Upside160.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
C4 Therapeutics News
PremiumCompany Announcements
C4 Therapeutics Appoints Steve Hoerter to Board
PremiumCompany Announcements
C4 Therapeutics Advances in Protein Degradation TherapyBulls Say, Bears Say
Bulls Say
Drug DevelopmentCFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.
Financial OutlookCemsidomide and CFT1946 make up $13 of the $20 target price, indicating significant value from these assets.
Safety And EfficacyCFT1946 tolerability looked better than inhibitors with overall good safety, no DLTs, dose reductions, or interruptions at any dose.
Bears Say
Efficacy ConcernsMost patients exhibited stable or progressive disease, and the level of efficacy is somewhat modest.
Market SentimentGiven negative Street sentiment for disappointing updates, CCCC shares could trade down to ~$4–5 in a Bear Case scenario (no efficacy or a poor safety profile).
Partnership UncertaintyCCCC has expressed its intent to partner the cemsidomide program, but a partnership has not yet been announced.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.06 and its highest was $11.88 in the past 12 months.
What is C4 Therapeutics’s market cap?
Currently, no data Available
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 91 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.379 by $0.029.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -$0.49.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 70,588,960 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.379. Following the earnings report the stock price went down -3.617%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Among the largest hedge funds holding C4 Therapeutics’s share is RA Capital Management. It holds C4 Therapeutics’s shares valued at 28M.
---
C4 Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.67 (160.88% Upside)
$10.67 (160.88% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 54.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
139.64%
12-Months-Change
Fundamentals
Return on Equity
-46.00%
Trailing 12-Months
Asset Growth
12.93%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
---
CCCC Stock 12 Month Forecast
Average Price Target
$10.67
▲(160.88% Upside)
Technical Analysis
Best Analysts Covering CCCC
1 Year
1 Year Success Rate
4/15 ratings generated profit
1 Year Average Return
-4.81%
reiterated a buy rating 22 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -4.81% per trade.
---